PYC Therapeutics Future Growth
Future criteria checks 1/6
PYC Therapeutics is forecast to grow earnings and revenue by 34.7% and 15.6% per annum respectively. EPS is expected to grow by 5.3% per annum. Return on equity is forecast to be -28.5% in 3 years.
Key information
34.7%
Earnings growth rate
5.3%
EPS growth rate
| Biotechs earnings growth | 15.3% |
| Revenue growth rate | 15.6% |
| Future return on equity | -28.4% |
| Analyst coverage | Low |
| Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 35 | -13 | -19 | 1 | 4 |
| 6/30/2026 | 35 | -19 | -37 | -29 | 4 |
| 6/30/2025 | 9 | -48 | -39 | -44 | 4 |
| 6/30/2024 | 22 | -38 | -39 | -39 | N/A |
| 3/31/2024 | 22 | -30 | -29 | -29 | N/A |
| 12/31/2023 | 21 | -22 | -20 | -19 | N/A |
| 9/30/2023 | 19 | -22 | -22 | -22 | N/A |
| 6/30/2023 | 16 | -23 | -25 | -24 | N/A |
| 3/31/2023 | 15 | -23 | -26 | -25 | N/A |
| 12/31/2022 | 14 | -24 | -26 | -26 | N/A |
| 9/30/2022 | 15 | -19 | -24 | -24 | N/A |
| 6/30/2022 | 16 | -14 | -22 | -22 | N/A |
| 3/31/2022 | 13 | -15 | -18 | -17 | N/A |
| 12/31/2021 | 9 | -17 | -14 | -13 | N/A |
| 9/30/2021 | 6 | -17 | -13 | -12 | N/A |
| 6/30/2021 | 3 | -18 | -12 | -12 | N/A |
| 3/31/2021 | 3 | -15 | -11 | -11 | N/A |
| 12/31/2020 | 2 | -12 | -10 | -10 | N/A |
| 9/30/2020 | 2 | -9 | -8 | -8 | N/A |
| 6/30/2020 | 2 | -7 | -6 | -6 | N/A |
| 3/31/2020 | 1 | -6 | -6 | -6 | N/A |
| 12/31/2019 | 0 | -5 | -6 | -6 | N/A |
| 9/30/2019 | 0 | -5 | -6 | -6 | N/A |
| 6/30/2019 | N/A | -4 | -6 | -5 | N/A |
| 3/31/2019 | 0 | -4 | -4 | -4 | N/A |
| 12/31/2018 | 0 | -5 | -3 | -3 | N/A |
| 9/30/2018 | 0 | -6 | -5 | -5 | N/A |
| 6/30/2018 | 0 | -7 | -7 | -7 | N/A |
| 3/31/2018 | 0 | -6 | N/A | -5 | N/A |
| 12/31/2017 | 0 | -5 | N/A | -3 | N/A |
| 9/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2017 | 3 | -2 | N/A | -2 | N/A |
| 3/31/2017 | 3 | -3 | N/A | -4 | N/A |
| 12/31/2016 | 3 | -4 | N/A | -6 | N/A |
| 9/30/2016 | 1 | -4 | N/A | -5 | N/A |
| 6/30/2016 | 0 | -4 | N/A | -3 | N/A |
| 3/31/2016 | 0 | -4 | N/A | -2 | N/A |
| 12/31/2015 | 0 | -4 | N/A | -1 | N/A |
| 9/30/2015 | 0 | -3 | N/A | -2 | N/A |
| 6/30/2015 | 1 | -3 | N/A | -2 | N/A |
| 3/31/2015 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2014 | 1 | -3 | N/A | -4 | N/A |
| 9/30/2014 | 1 | -3 | N/A | -4 | N/A |
| 6/30/2014 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2014 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2013 | 1 | -3 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PYCDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PYCDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PYCDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PYCDA's revenue (15.6% per year) is forecast to grow faster than the Australian market (5.8% per year).
High Growth Revenue: PYCDA's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PYCDA is forecast to be unprofitable in 3 years.